Gastric Cancer Drugs Market Size, Insights, Outlook, and Overview by 2024-2033

Overview and Scope

Gastric cancer drugs refer to anti-cancer medications that are taken orally as pills or are injected into a vein (via an IV line or central venous catheter). This treatment is effective for cancer that has spread to organs other than those where it originated since these medications penetrate the bloodstream and reach every part of the body.

Sizing and Forecast

The gastric cancer drugs market size has grown rapidly in recent years. It will grow from $3.91 billion in 2023 to $4.41 billion in 2024 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to increase in pharmaceutical r&d expenditure, increased healthcare expenditure, strong economic growth in emerging markets and rapid growth in elderly population.

The gastric cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $6.92 billion in 2028 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to increase in gastric cancer incidence rate, strong pipeline of drugs, rise in acquisitions and partnerships for drug development, rise in healthcare expenditure high potential in emerging economies, increasing geriatric population and revised fda regulations to facilitate biologics drug development. Major trends in the forecast period include strategic collaborations and agreements to broaden product portfolios, collaborating and partnering with other companies or government bodies to accelerate the development of new drugs, increasing the number of pipeline studies to develop gastric cancer drugs, investing in ai solutions, to reduce r&d costs, development of next-generation biologics to increase revenue and market share and using crispr-cas9 technology in new drugs developments or for better results in gastric cancer treatments.

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Segmentation & Regional Insights

The gastric cancer drugs market covered in this report is segmented –

1) By Type: Imatinib, Trastuzumab, Other Types
2) By Route of Administration: Oral, Parenteral
3) By End User: Hospitals, Clinics, Cancer Speciality Centers

North America was the largest region in the gastric cancer drugs market in 2023. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp

Major Driver Impacting Market Growth

An increasing number of obesity cases and the smoking population increased the number of people suffering from gastric cancer. Consuming tobacco and following diet unhealthy diet increases the risk of stomach cancer. According to the estimates of the American Institute for Cancer Research for 2020, about 27,600 cases of stomach cancer will be diagnosed (16,980 in men and 10,620 in women). An increase in several cases of gastric cancer will drive for the growth of the gastric cancer drugs market.

Key Industry Players

Major companies operating in the gastric cancer drugs market report are F. Hoffmann-La Roche, Eli Lilly and Company, Otsuka Pharmaceutical, Jiangsu HengRui Medicine, Biocon, Sanofi, PV Pharma Healthcare (India), Roche India, Novartis Oncology, Arlak Biotech (India), Healthkind labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz biotech., CStone Pharma (China), CARsgen Therapeutics (China), JW Therapeutics (China), BeiGene(China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc (Japan), Daiichi Pharmaceutical and Sankyo (Japan), AQVIDA GmbH, Baxter International Inc. (UK), AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celltrion Inc., Imugene Limited, Merck & Co. Inc., Pfizer Inc., Sandoz AG (A Novartis Division), Eurofarma Laboratórios S.A., TUTEUR ArgentinaPierre Fabre Group, Celnova Pharma, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO), Gulf Pharmaceutical Industries (Julphar), Abbott Laboratories, Mylan Laboratories, GSK, Gilead Sciences, BMS, Ascedis Health

The gastric cancer drugs market report table of contents includes:

1. Executive Summary

2. Gastric Cancer Drugs Market Characteristics

3. Gastric Cancer Drugs Market Trends And Strategies

4. Gastric Cancer Drugs Market – Macro Economic Scenario

5. Global Gastric Cancer Drugs Market Size and Growth

…

32. Global Gastric Cancer Drugs Market Competitive Benchmarking

33. Global Gastric Cancer Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Gastric Cancer Drugs Market

35. Gastric Cancer Drugs Market Future Outlook and Potential Analysis

36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model